Trials / Completed
CompletedNCT03267589
Trial in Patients With Relapsed Ovarian Cancer
NSGO-OV-UMB1; ENGOT-OV30 / NSGO: A Phase II Umbrella Trial in Patients With Relapsed Ovarian Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The overall objectiv is to obtain preliminary evidence of efficacy of novel agents for the management of relapsed ovarian cancer, and in part 2 efficacy of novel agents compared to the standard of care (SoC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562 | Three different combination are being tested. Each cohort has different combination |
Timeline
- Start date
- 2018-05-14
- Primary completion
- 2021-10-19
- Completion
- 2021-10-19
- First posted
- 2017-08-30
- Last updated
- 2025-07-29
Locations
5 sites across 3 countries: Denmark, Finland, Norway
Source: ClinicalTrials.gov record NCT03267589. Inclusion in this directory is not an endorsement.